Biocom California Selects New Chair for its Board of Directors
Retrieved on:
Monday, January 10, 2022
Research, Medical Devices, Professional Services, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Other Professional Services, CONNECT, Research, LinkedIn, Biotechnology, Biology, Division, Genomics, Conrad, Female, Single-frequency network, Public policy, Therapy, Cancer, Association, Heparin, RNA, COVID-19, Tulane University School of Medicine, State Bar of California, STEM, Infection, Advisory Council, Baxter International, Patient, Solution, CFO, Glycogen storage disease, Claudia Shear, University of California, San Diego, University, San Francisco Bay Area, UC, CEO, Photography, 4th Tony Awards, Goal, La Jolla Playhouse, Dean, TEGA, Project Concern International, VIII, Board, Pharmaceutical industry, Biochemistry, Facebook, Twitter
Biocom California, the association representing the California life science industry, today announced that it has named a new board chair and chair elect.
Key Points:
- Biocom California, the association representing the California life science industry, today announced that it has named a new board chair and chair elect.
- Timothy Scott, CEO of TEGA Therapeutics is the new chair, and Sabrina Martucci Johnson, CEO of Dar Bioscience, is the chair elect.
- These board leadership positions are crucial for shaping Biocom Californias goals and implementing new programs, said Joe Panetta, president and CEO of Biocom California.
- In addition to announcing the new chair and chair elect, Biocom California also named the remainder of its board officers, who are as follows:
Biocom California is the leader and advocate for Californias life science sector.